KRAS and plasma cell myeloma: Recently, a potent and selective antisense oligonucleotide AZD4785 has been chosen to target and downregulate all KRAS isoforms and demonstrated its ability to silence KRAS and to inhibit multiple myeloma-tumor-bearing KRAS mutations [104].